Dermatitis News and Research

Latest Dermatitis News and Research

Varian presents first preclinical results of breakthrough cancer therapy research

At the American Association for Cancer Research Annual Meeting in Atlanta, GA, Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high dose rate cancer treatments with protons.

From American Association for Cancer Research-AACR Annual Meeting 2019 8 Apr 2019

Study suggests potential new approach to treat atopic dermatitis

How does the immune system respond to fungi on our skin? Researchers at the University of Zurich have demonstrated that the same immune cells that protect us against skin fungi also encourage the inflammatory symptoms of atopic dermatitis. An antibody therapy could alleviate this chronic inflammatory skin disease.

18 Mar 2019

Higher rates of anxiety and depression found among patients with atopic dermatitis

A British Journal of Dermatology study has found substantially higher rates of anxiety and depression among US adults with atopic dermatitis, compared to those without. The study also found that anxiety and depression often go undiagnosed in these individuals.

6 Mar 2019

Scientists demonstrate key role of salt in allergic immune reactions

Salt apparently affects allergic immune reactions. A team working with Prof. Christina Zielinski at the Technical University of Munich has demonstrated in cell cultures that salt leads to the formation of Th2 cells.

21 Feb 2019

Research reveals critical immunological axis that triggers cancer-promoting chronic inflammation

A Massachusetts General Hospital research team has identified interaction between two elements of the immune system as critical for the transformation of a protective immune response into chronic, cancer-promoting inflammation.

12 Feb 2019

Researchers identify comprehensive guidelines for managing severe atopic dermatitis

A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD), the most common form of eczema.

16 Jan 2019

Pharmacists could significantly reduce ED crowdedness

Incorporating pharmacists with an expanded scope into the community or hospital emergency departments (ED) could significantly reduce ED crowdedness, according to a new study.

10 Jan 2019

Investigational topical cream may be effective for treating atopic dermatitis

A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream may be effective for treating atopic dermatitis, one of the most common inflammatory skin diseases.

9 Jan 2019

Dermatology providers show interest in recommending cannabinoids to patients

The cannabis plant and its derivatives have been used in medicinal treatments for millennia. With the recent legalization of medical marijuana in 33 states across the country, as well as Washington, D.C., several specialties are weighing the possibilities of integrating cannabinoids into patient therapies, including dermatology.

11 Dec 2018

Surprising discovery about BH4 may rekindle interest in once-promising pathway

In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, PhD, and chemist Kai Johnsson, PhD, his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief.

19 Nov 2018

Atopic dermatitis found to be highly prevalent among adults in the U.S.

As many as 16.5 million adults in America suffer from a skin disease known as atopic dermatitis, an inflammatory disease that results in red, itchy skin.

30 Oct 2018

That’s a lot of scratch: The $48,329 allergy test

Janet Winston had a rash that wouldn't go away. The English professor from Eureka, Calif., always had been sensitive to ingredients in skin creams and cosmetics. This time, however, the antifungal cream she was prescribed to treat her persistent rash seemed to make things worse. Was she allergic to that, too?

29 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Dermatitis News and Research

Latest Dermatitis News and Research

Varian presents first preclinical results of breakthrough cancer therapy research

Study suggests potential new approach to treat atopic dermatitis

Higher rates of anxiety and depression found among patients with atopic dermatitis

Scientists demonstrate key role of salt in allergic immune reactions

Research reveals critical immunological axis that triggers cancer-promoting chronic inflammation

Researchers identify comprehensive guidelines for managing severe atopic dermatitis

Pharmacists could significantly reduce ED crowdedness

Investigational topical cream may be effective for treating atopic dermatitis

Dermatology providers show interest in recommending cannabinoids to patients

Surprising discovery about BH4 may rekindle interest in once-promising pathway

Atopic dermatitis found to be highly prevalent among adults in the U.S.

That’s a lot of scratch: The $48,329 allergy test

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Online and in-person care found to be equally effective at improving psoriasis symptoms

Study reveals promising new drug candidate to treat acute renal failure

Robert Koch Institute publishes new data on allergies, mental health problems, and accident injuries

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Dermatitis News and Research

Latest Dermatitis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in